Document is current
Any future updates will be listed below
-
Authors
Hoy, Gregory
Cortier, Thomas
Maier, Hannah E. https://orcid.org/0000-0001-5761-0801
Kuan, Guillermina
Lopez, Roger
Sanchez, Nery
Ojeda, Sergio
Plazaola, Miguel
Stadlbauer, Daniel
Shotwell, Abigail
Balmaseda, Angel
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Cauchemez, Simon https://orcid.org/0000-0001-9186-4549
Gordon, Aubree https://orcid.org/0000-0002-9352-7877
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (75N93019C00051)
U.S. Department of Health & Human Services | National Institutes of Health (HHSN272201400006C)
U.S. Department of Health & Human Services | National Institutes of Health (75N93021C00016)
U.S. Department of Health & Human Services | National Institutes of Health (R01 AI120997)
- License Information
-
More Information
Article History
Received: 29 July 2025
Accepted: 8 October 2025
First Online: 11 December 2025
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications related to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines and influenza virus therapeutics, which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, CastleVax, to develop SARS-CoV-2 vaccines. Florian Krammer is a co-founder and scientific advisory board member of CastleVax. Florian Krammer has consulted for Merck, CureVac, Seqirus, GSK and Pfizer and is currently consulting for 3rd Rock Ventures, Gritstone and Avimex. The Krammer laboratory is collaborating with Dynavax on influenza vaccine development. Aubree Gordon has served on an RSV vaccine advisory board for Janssen. All other authors declare no competing interests.
